Literature DB >> 16557207

The value of FDG-PET in the follow-up of differentiated thyroid cancer: a review of the literature.

M P M Stokkel1, C S J Duchateau, C Dragoiescu.   

Abstract

Well differentiated (follicular and papillary) thyroid cancer (DTC) is characterized by rare occurrence and a good prognosis. However, up to 20% of patients with DTC develop locoregional recurrences, whereas even 8% of patients with such recurrences will eventually die from disease. In some of these patients it is related to incomplete initial treatment, whereas in others it indicates the presence of an aggressive tumor. In this latter case, dedifferentiation may occur with negative I-131 whole body scintigraphy (WBS) results and unreliable Tg measurements. In patients with thyroid cancer metastases that lost the capability of I-131 uptake, other imaging techniques are required to depict the non-functioning metastases, irrespective of the Tg-levels and irrespective of the site of recurrent disease. In this respect, some reports have discussed the value of ultrasonography of the head and neck region with good results for the detection of locoregional disease. We have assessed the role of FDG-PET in patients with I-131 negative WBS and its relation with Tg values and TSH-stimulation based on data that have appeared in the literature. In this review article, a discussion is given on the results published so far.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16557207

Source DB:  PubMed          Journal:  Q J Nucl Med Mol Imaging        ISSN: 1824-4785            Impact factor:   2.346


  18 in total

1.  Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET.

Authors:  L S Freudenberg; G Antoch; A Frilling; W Jentzen; S J Rosenbaum; H Kühl; A Bockisch; R Görges
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-12       Impact factor: 9.236

2.  (68)Ga-somatostatin analogues PET and (18)F-DOPA PET in medullary thyroid carcinoma.

Authors:  Valentina Ambrosini; Maria Cristina Marzola; Domenico Rubello; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

Review 3.  The next generation of positron emission tomography radiopharmaceuticals in oncology.

Authors:  Samuel L Rice; Celeste A Roney; Pierre Daumar; Jason S Lewis
Journal:  Semin Nucl Med       Date:  2011-07       Impact factor: 4.446

Review 4.  Role of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography in patients affected by differentiated thyroid carcinoma, high thyroglobulin level, and negative ¹³¹I scan: review of the literature.

Authors:  Francesco Bertagna; Giorgio Biasiotto; Emanuela Orlando; Giovanni Bosio; Raffaele Giubbini
Journal:  Jpn J Radiol       Date:  2010-11-27       Impact factor: 2.374

5.  ¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy.

Authors:  Sandra J Rosenbaum-Krumme; Rainer Görges; Andreas Bockisch; Ina Binse
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-06-21       Impact factor: 9.236

6.  Relations Between Pathological Markers and Radioiodine Scan and (18)F-FDG PET/CT Findings in Papillary Thyroid Cancer Patients With Recurrent Cervical Nodal Metastases.

Authors:  Jeong Won Lee; Hye Sook Min; Sang Mi Lee; Hyun Woo Kwon; June-Key Chung
Journal:  Nucl Med Mol Imaging       Date:  2015-02-13

7.  Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography.

Authors:  A Reum Chun; Hye Min Jo; Seoung Ho Lee; Hong Woo Chun; Jung Mi Park; Kyu Jin Kim; Chan Hee Jung; Ji Oh Mok; Sung Koo Kang; Chul Hee Kim; Bo Yeon Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2014-07-18

8.  Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer.

Authors:  Lutz S Freudenberg; Andrea Frilling; Hilmar Kühl; Stefan P Müller; Walter Jentzen; Andreas Bockisch; Gerald Antoch
Journal:  Eur Radiol       Date:  2007-05-22       Impact factor: 5.315

Review 9.  Current molecular imaging positron emitting radiotracers in oncology.

Authors:  Aizhi Zhu; Hyunsuk Shim
Journal:  Nucl Med Mol Imaging       Date:  2011-02-01

10.  Primary bone lymphoma of the mandible and thyroid incidentaloma identified by FDG PET/CT: a case report.

Authors:  Joaquim Bosch-Barrera; Leire Arbea; Maria J García-Velloso; Ignacio Gil-Bazo; Jesús García-Foncillas; Carlos Panizo
Journal:  Cases J       Date:  2009-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.